Castle Biosciences (CSTL) Share-based Compensation (2018 - 2026)

Castle Biosciences has reported Share-based Compensation for 9 years, with the latest figure at $11.6 million in Q2 2026.

• Quarterly Share-based Compensation rose 3.4% year-over-year to $11.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $44.9 million (down 4.23% YoY) and the FY2025 annual result came in at $45.9 million, down 8.8% from the prior year.
• Share-based Compensation climbed to $11.6 million in Q2 2026 per CSTL's latest filing, from $9.8 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $13.5 million in Q1 2023 and troughed at $8.4 million in Q1 2022.
• A 5-year average of $11.4 million and a median of $11.5 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 84.28% in 2022, then declined 14.96% in 2025.
• Over 5 years, Share-based Compensation stood at $9.9 million in 2022, then gained by 18.94% to $11.8 million in 2023, then slipped by 3.08% to $11.4 million in 2024, then slipped by 0.29% to $11.4 million in 2025, then climbed by 1.6% to $11.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $11.6 million, $9.8 million, and $11.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.